Median Technologies: H2 2025 Financial Communication Calendar

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:

Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis^®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announces today its H2 2025 financial communication calendar.

The Company will participate in upcoming investor events:

European MidCap Event 2025
September 30 – October 1st, 2025 - Paris, France

Portzamparc Biotech and Healthcare Sector Investor Seminar
October 1-2, 2025 (digital)

Investor Access Conference 2025
October 7-8, 2025 - Paris, France

Please get in touch through the respective event booking systems, if you would like to request a meeting with Median management at these events. Events are for institutional investors only.

About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis^®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.